Related Experiment Video
Updated: Jul 13, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Targeting uPA/uPAR in prostate cancer
1Cancer Care Centre, St. George Hospital, Gray Street, Kogarah, NSW 2217, Australia. y.li@unsw.edu.au
Cancer Treatment Reviews
|July 31, 2007
Summary
Prostate cancer (CaP) metastasis is driven by urokinase plasminogen activator (uPA) and its receptor (uPAR). Targeting uPA/uPAR offers a promising therapeutic strategy for advanced CaP.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer (CaP) is a prevalent malignancy in men, with rising incidence.
- Tumor cell invasion is critical for CaP metastasis and treatment failure.
- Urokinase plasminogen activator (uPA) and its receptor (uPAR) signaling are implicated in cancer progression.
Purpose of the Study:
- To review new findings on the role of uPA/uPAR in prostate cancer progression.
- To establish the potential of uPA/uPAR-targeted therapies for CaP.
Main Methods:
- Literature review summarizing recent research on uPA/uPAR in prostate cancer.
- Analysis of studies investigating the expression patterns and functional roles of uPA and uPAR in CaP tissues.
- Evaluation of preclinical and clinical data on targeted therapies.
Main Results:
- uPA and uPAR are significantly overexpressed in CaP tissues compared to benign and normal tissues.
- uPA/uPAR signaling pathways are crucial for CaP cell invasion, survival, and metastasis.
- Aberrant uPA/uPAR expression serves as a diagnostic marker and therapeutic target in CaP progression.
Conclusions:
- uPA/uPAR play a critical role in driving prostate cancer progression and metastasis.
- Targeting uPA/uPAR represents a promising therapeutic avenue for hormone-refractory prostate cancer (HRPC).
- Further research into uPA/uPAR-targeted therapies is warranted for improved CaP treatment outcomes.
